Key Insights

Highlights

Success Rate

96% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

2.0%

1 terminated out of 51 trials

Success Rate

95.7%

+9.1% vs benchmark

Late-Stage Pipeline

20%

10 trials in Phase 3/4

Results Transparency

14%

3 of 22 completed with results

Key Signals

3 with results96% success

Data Visualizations

Phase Distribution

31Total
Not Applicable (16)
P 1 (2)
P 2 (3)
P 3 (6)
P 4 (4)

Trial Status

Completed22
Unknown20
Recruiting2
Active Not Recruiting2
Not Yet Recruiting2
Withdrawn1

Trial Success Rate

95.7%

Benchmark: 86.5%

Based on 22 completed trials

Clinical Trials (51)

Showing 20 of 20 trials
NCT06340269Not ApplicableCompleted

Feasibility Pilot Study to Evaluate the Safety and Performance of the MEX-CD1 Medical Device in ACLF

NCT07362173Phase 4Active Not Recruiting

Actualities in Procedural Sedation: Remimazolam

NCT07404358Phase 3Active Not Recruiting

Dalargin for Prevention of Organ Disfunction in High-Risk Abdominal Surgery

NCT04288635Recruiting

Impact of Metabolite Supplementation to Restore Mitochondrial Dysfunction During Septic Shock: a Preclinical Study

NCT03721952Not ApplicableCompleted

Facilitating Communication Study

NCT06050525Completed

Incidence of Acute Kidney Injury and Risk Factors in Newborns With Congenital Diaphragmatic Hernia

NCT03895853Phase 2TerminatedPrimary

Early Metabolic Resuscitation for Septic Shock

NCT06371677Not Yet Recruiting

Polish Nationwide Register of Hospitalized Patients in Cardiac Intensive Care Units

NCT04094428Recruiting

Burden, Mortality and Supply Costs in Intensive Care Unit Patients

NCT01363635Unknown

Severe Sepsis/Septic Shock on Admission to the General Surgical ICU

NCT03968640Phase 3WithdrawnPrimary

Efficacy of Coenzyme Q10 Supplementation on Multi-Organ Dysfunction in Severely Burned Patients

NCT04306419Unknown

Observational Trial on Cytokine Adsorption in Sepsis

NCT05182723Not ApplicableUnknown

Evaluation of the Effectiveness of Extracorporeal Methods for Removing Mediators of Systemic Inflammation

NCT05090930Not ApplicableUnknown

Innovative Technologies for the Treatment of Pulmonary and Heart Failure

NCT04392778Phase 1Completed

Clinical Use of Stem Cells for the Treatment of Covid-19

NCT00133978Not ApplicableCompleted

Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients

NCT03345992Phase 3Completed

Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System

NCT04295278UnknownPrimary

Feasibility Study of MicroKine Dx System in Critically-ill Pediatric Patients.

NCT04356300Not ApplicableNot Yet RecruitingPrimary

Exosome of Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection

NCT02906345Not ApplicableUnknownPrimary

TPE in Septic Patients and Influence on Organ Failure

Scroll to load more

Research Network

Activity Timeline